Luminal
(Phenobarbital)ApprovedSmall molecule
Sun Pharmaceutical Industries, Inc.Phenobarbital is used to treat seizures and epilepsy, and is also sometimes used as a sedative to help people sleep or reduce anxiety.[2] Luminal is currently approved and in use across 4 indications[4].[1]
Luminal is one of 79 small molecule programs targeting Neonatal seizure. It is currently in Approved.
4
Indications
25
Total Trials
3
Active Trials
78
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
2
Patents
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
87 competitors in Epilepsy
#DrugCompanyPhaseTrials
1Tegretol
NovartisApproved
Trileptal
NovartisApproved
Fycompa
CCatalyst Biosciences
Approved
Avelox
BayerApproved
Thalomid
Bristol-Myers SquibbApproved
Briviact
UCBPhase 3
Dilantin
VViatris Specialty LLC
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Epidiolex
Jazz PharmaceuticalsPhase 3
Ketalar
AAultman Health Foundation
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neonatal seizure6 trials
Efficacy of Levetiracetam in Control of Neonatal Seizures Guided by an EEG
Unknown status·—·Phase 4·NCT03107507·40 enrolled
Show 3 more trials
Status Epilepticus4 trials
Neonatal Abstinence Syndrome3 trials
Seizure3 trials
7 more indications
Lymphoma1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Nov 17, 2022
SEZABY
NDA NDA215910
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Luminal drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Phenobarbital. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]